TransCode Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
12
- Stock Symbol
-
RNAZ
- Investments
-
1
- Share Price
-
$1.32
- (As of Friday Closing)
TransCode Therapeutics General Information
Description
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Contact Information
Website
www.transcodetherapeutics.comCorporate Office
- 6 Liberty Square
- Suite 2382
- Boston, MA 02109
- United States
Corporate Office
- 6 Liberty Square
- Suite 2382
- Boston, MA 02109
- United States
TransCode Therapeutics Stock Performance
As of 13-Nov-2026, TransCode Therapeutics’s stock price is $1.32. Its current market cap is $22.3M with 16.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.32 | $1.39 | $1.30 - $12.60 | $22.3M | 16.9M | 53.5K | -$52.06 |
TransCode Therapeutics Financials Summary
As of 30-Jun-2026, TransCode Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 136,336 | 3,427 | 623 | (2,722) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (42,496) | (34,393) | (16,194) | (17,979) |
| Net Income | (42,834) | (34,661) | (16,755) | (18,546) |
| Total Assets | 151,010 | 162,399 | 7,294 | 5,170 |
| Total Debt | 652 | 0 | 38 | 451 |
TransCode Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TransCode Therapeutics Comparisons
Industry
Financing
Details
TransCode Therapeutics Competitors (10)
One of TransCode Therapeutics’s 10 competitors is Ionis Pharmaceuticals, a Corporate Backed or Acquired company based in Carlsbad, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals | Corporate Backed or Acquired | Carlsbad, CA | ||||
| Black Diamond Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Moderna | Formerly VC-backed | Cambridge, MA | ||||
| BioNTech | Formerly VC-backed | Mainz, Germany | ||||
| Nurix Therapeutics | Formerly VC-backed | San Francisco, CA |
TransCode Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
TransCode Therapeutics Patents
TransCode Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4547258-A1 | Nanoparticles and template directed rig-i agonist precursor compositions and uses thereof for cancer therapy | Pending | 28-Jun-2022 | ||
| EP-4547258-A4 | Nanoparticles and template directed rig-i agonist precursor compositions and uses thereof for cancer therapy | Pending | 28-Jun-2022 | ||
| US-20240042070-A1 | Nanoparticles and template directed rig-i agonist precursor compositions and uses thereof for cancer therapy | Pending | 28-Jun-2022 | ||
| WO-2024006362-A1 | Nanoparticles and template directed rig-i agonist precursor compositions and uses thereof for cancer therapy | Inactive | 28-Jun-2022 | ||
| AU-2021413862-A1 | Template directed immunomodulation for cancer therapy | Pending | 30-Dec-2020 | A61K48/00 |
TransCode Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TransCode Therapeutics Acquisitions (1)
TransCode Therapeutics’s most recent deal was a Merger/Acquisition with Polynoma. The deal was made on 08-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Polynoma | 08-Oct-2025 | Merger/Acquisition | Drug Discovery |
TransCode Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
TransCode Therapeutics FAQs
-
When was TransCode Therapeutics founded?
TransCode Therapeutics was founded in 2016.
-
Where is TransCode Therapeutics headquartered?
TransCode Therapeutics is headquartered in Boston, MA.
-
What is the size of TransCode Therapeutics?
TransCode Therapeutics has 12 total employees.
-
What industry is TransCode Therapeutics in?
TransCode Therapeutics’s primary industry is Biotechnology.
-
Is TransCode Therapeutics a private or public company?
TransCode Therapeutics is a Public company.
-
What is TransCode Therapeutics’s stock symbol?
The ticker symbol for TransCode Therapeutics is RNAZ.
-
What is the current stock price of TransCode Therapeutics?
As of 13-Nov-2026 the stock price of TransCode Therapeutics is $1.32.
-
What is the current market cap of TransCode Therapeutics?
The current market capitalization of TransCode Therapeutics is $22.3M.
-
Who are TransCode Therapeutics’s competitors?
Ionis Pharmaceuticals, Black Diamond Therapeutics, Moderna, BioNTech, and Nurix Therapeutics are some of the 10 competitors of TransCode Therapeutics.
-
What is TransCode Therapeutics’s annual earnings per share (EPS)?
TransCode Therapeutics’s EPS for 12 months was -$52.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
